When evaluating the pCR by age subgroup, hormone receptor, tumor size, and nodal status, we identified a trend toward a higher pCR in the T3-T4, N+, and HR+ subgroups in the AC-THP arm, with significance only for the population with nodal involvement in favor of the anthracycline arm, odds ratio (OR) 0.60 (0.37–0.95) (Figure 3). The gene discussed is NR4A1; the disease is neoplasm.